Wyeth and WHO launch Phase III trial for river blindness drug
This article was originally published in Scrip
Executive Summary
Wyeth Pharmaceuticals has launched Phase III trials in three African countries to test reformulated animal antiparasitic moxidectin as a treatment for river blindness, a disease caused by the parasite Onchocerca volvulus that results in loss of sight, rashes and skin lesions.